Masaharu Somiya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5080449/publications.pdf

Version: 2024-02-01

37	764	623188	525886
papers	citations	14 h-index	27 g-index

43	43	43	1009
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biocompatibility of highly purified bovine milkâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2018, 7, 1440132.	5.5	168
2	Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials, 2021, 268, 120601.	5.7	67
3	Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Advanced Drug Delivery Reviews, 2015, 95, 77-89.	6.6	52
4	Current Progress of Virus-mimicking Nanocarriers for Drug Delivery. Nanotheranostics, 2017, 1, 415-429.	2.7	47
5	Where does the cargo go?: Solutions to provide experimental support for the â€œextracellular vesicle cargo transfer hypothesisâ€• Journal of Cell Communication and Signaling, 2020, 14, 135-146.	1.8	40
6	Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy. Scientific Reports, 2012, 2, 790.	1.6	39
7	Cellular uptake of hepatitis B virus envelope L particles is independent of sodium taurocholate cotransporting polypeptide, but dependent on heparan sulfate proteoglycan. Virology, 2016, 497, 23-32.	1.1	32
8	Real-Time Luminescence Assay for Cytoplasmic Cargo Delivery of Extracellular Vesicles. Analytical Chemistry, 2021, 93, 5612-5620.	3.2	31
9	Drug delivery application of extracellular vesicles; insight into production, drug loading, targeting, and pharmacokinetics. AIMS Bioengineering, 2017, 4, 73-92.	0.6	27
10	Development of a macrophage-targeting and phagocytosis-inducing bio-nanocapsule-based nanocarrier for drug delivery. Acta Biomaterialia, 2018, 73, 412-423.	4.1	26
11	Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine, 2021, 39, 3313-3314.	1.7	23
12	Intracellular trafficking of bio-nanocapsuleâ€“liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein. Journal of Controlled Release, 2015, 212, 10-18.	4.8	22
13	Reporter gene assay for membrane fusion of extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12171.	5.5	21
14	CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells. Journal of Nanobiotechnology, 2018, 16, 59.	4.2	20
15	One-step scalable preparation method for non-cationic liposomes with high siRNA content. International Journal of Pharmaceutics, 2015, 490, 316-323.	2.6	17
16	Oriented immobilization to nanoparticles enhanced the therapeutic efficacy of antibody drugs. Acta Biomaterialia, 2019, 86, 373-380.	4.1	14
17	Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy. International Journal of Nanomedicine, 2015, 10, 4159.	3.3	13
18	A hepatitis B virus-derived human hepatic cell-specific heparin-binding peptide: identification and application to a drug delivery system. Biomaterials Science, 2019, 7, 322-335.	2.6	13

#	Article	IF	Citations
19	Mutational analysis of hepatitis B virus pre-S1 (9â€“24) fusogenic peptide. Biochemical and Biophysical Research Communications, 2016, 474, 406-412.	1.0	10
20	Induction of lipid droplets in non-macrophage cells as well as macrophages by liposomes and exosomes. Biochemical and Biophysical Research Communications, 2019, 510, 184-190.	1.0	10
21	Engineering of Extracellular Vesicles for Small Molecule-Regulated Cargo Loading and Cytoplasmic Delivery of Bioactive Proteins. Molecular Pharmaceutics, 2022, 19, 2495-2505.	2.3	10
22	Targeting of polyplex to human hepatic cells by bio-nanocapsules, hepatitis B virus surface antigen L protein particles. Bioorganic and Medicinal Chemistry, 2012, 20, 3873-3879.	1.4	9
23	Elucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsule. World Journal of Gastroenterology, 2016, 22, 8489.	1.4	8
24	Low immunogenic bio-nanocapsule based on hepatitis B virus escape mutants. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 595-600.	1.7	7
25	Release of siRNA from Liposomes Induced by Curcumin. Journal of Nanotechnology, 2016, 2016, 1-6.	1.5	5
26	A regulatory role of scavenger receptor class B type 1 in endocytosis and lipid droplet formation induced by liposomes containing phosphatidylethanolamine in HEK293T cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118859.	1.9	5
27	HBV Pre-S1-Derived Myristoylated Peptide (Myr47): Identification of the Inhibitory Activity on the Cellular Uptake of Lipid Nanoparticles. Viruses, 2021, 13, 929.	1.5	4
28	Cytoplasmic delivery of small interfering RNA by photoresponsive non-cationic liposomes. Journal of Drug Delivery Science and Technology, 2021, 63, 102488.	1.4	4
29	In vivouterine local gene delivery system using TATâ€displaying bionanocapsules. Journal of Gene Medicine, 2019, 21, e3140.	1.4	3
30	Virus-mimicking nanocarriers for the intracellular delivery of therapeutic biomolecules. Nanomedicine, 2020, 15, 1163-1165.	1.7	3
31	Recent advances in animal cell technologies for industrial and medical applications. Journal of Bioscience and Bioengineering, 2022, 133, 509-514.	1.1	3
32	Potential of a non-cationic liposomes-based delivery system for nucleic acid medicines. Drug Delivery System, 2016, 31, 35-43.	0.0	1
33	Polymerized Albumin Receptor of Hepatitis B Virus for Evading the Reticuloendothelial System. Pharmaceuticals, 2021, 14, 408.	1.7	1
34	Construction of a Macrophage-Targeting Bio-nanocapsule-Based Nanocarrier. Methods in Molecular Biology, 2020, 2059, 299-313.	0.4	1
35	Biomimetic strategy for development of pleiotropic DDS carriers. Drug Delivery System, 2017, 32, 156-157.	0.0	0
36	Carrier development for biopharmaceuticals: Bio-nanocapsules based on the early infection machinery of hepatitis B virus. Drug Delivery System, 2020, 35, 57-63.	0.0	0

#	Article	IF	Citations
37	Comment on â€œCutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccinesâ€• Journal of Immunology, 2022, 208, 1833.2-1833.	0.4	0